Ten years of sensitivity monitoring in Europe (1994-2005)

Cefquinome gained market authorisation for the treatment of bovine pneumonia in 1994. Merck Animal Health simultaneously implemented a surveillance program to monitor the susceptibility of relevant bacteria against cefquinome.

Method

650 P.multocida and 492 M.haemolytica were isolated from bovine respiratory disease in Europe from 1994 to 2005.

Minimum inhibitory concentrations were determined and minimum bactericidal concentrations (MBC) were determined for the pathogens isolated during 2000-2005. MIC₅₀ and MIC₉₀ were determined annually for each strain.

Result

Results of the activity of cefquinome against P. multocida and M. haemolytica

Pathogen	MIC50	MIC90
P. multocida	≤0.032 µg/ml (1994-2004)	≤ 0.063 µg/ml (1994)  ≤ 0.25 µg/ml (1995)  ≤0.032 µg/ml (1994-2004)
M. haemolytica	≤0.032 µg/ml (1994-2004)	0.063 µg/ml (1995-1996)  0.016µg/ml

Conclusion

Results demonstrate that cefquinome shows an unchanged high activity against the main respiratory pathogens P.multocida and M.haemolytica isolated during the last ten years in Europe. Bactericidal activity against both bacteria was shown at very low concentrations.